| Patient | Frederick Law Olmsted |
|---|---|
| Date of birth | 1953-04-26 |
| Identifiers | MRN HR-NI022-SYN; SSN (made up) 000-22-5519 |
| Document date | 2026-11-01 |
| Author | Nathan Calder, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Cognitive evaluation for progressive memory loss: history from patient and caregiver, MoCA, function, mood, safety, and reversible-cause tests. Concerns: He is frustrated that he can no longer keep the details of his projects in mind and wants to understand what is happening; His caregiver wants to keep him safe at home and needs help and information. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Donepezil 5 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning with breakfast | Oral route | 2026-06-02 to 2026-08-04 | completed | S |
| Donepezil 10 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning with breakfast | Oral route | 2026-08-04 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| MRI of the brain without contrast: generalized cortical atrophy beyond that expected for age, with mild bilateral medial temporal atrophy (MTA score 2) and scattered small white-matter hyperintensities (Fazekas grade 1); no infarct, hemorrhage, mass, or hydrocephalus | 2026-05-19 to 2026-05-19 | completed | S |
| Advance care planning conversation with the patient and his caregiver, about 30 minutes | 2026-08-04 to 2026-08-04 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-21 | High-dose influenza vaccine, 2025-2026 season | completed | S |
| 2026-09-15 | High-dose influenza vaccine, 2026-2027 season | completed | S |
| 2026-09-15 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-09-15 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1863 | Exhaustion and illness from overwork while leading a national wartime relief commission, ending in his resignation in 1863; illness not specified in the cited source | D (CLM-0009) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He is frustrated that he can no longer keep the details of his projects in mind and wants to understand what is happening | active | S |
| His caregiver wants to keep him safe at home and needs help and information | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.1 on 2026-05-05; Leukocytes [#/volume] in Blood by Automated count 6.2 on 2026-05-05; Platelets [#/volume] in Blood by Automated count 238 on 2026-05-05; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-05-05; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-05-05; Creatinine [Mass/volume] in Serum or Plasma 1.02 on 2026-05-05; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 76 on 2026-05-05; Glucose [Mass/volume] in Serum or Plasma 94 on 2026-05-05; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-05-05; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-05-05; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-05-05; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 410 on 2026-05-05; Folate [Mass/volume] in Serum or Plasma 12.4 on 2026-05-05; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-05-05; Total score [MoCA] 19 on 2026-05-05; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-10-27; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-09-15; Total score [AUDIT-C] 0 on 2026-09-15; Cholesterol [Mass/volume] in Serum or Plasma 196 on 2026-09-15; Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 on 2026-09-15; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 118 on 2026-09-15; Triglyceride [Mass/volume] in Serum or Plasma 120 on 2026-09-15 [S]
Strengths and supports: Supports: his primary caregiver, family at home, long-time colleagues who visit, and a lifelong love of gardens and walking [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Mild dementia (major neurocognitive disorder), progressive, amnestic-predominant with executive difficulty, type undetermined; CDR global 1 | active | confirmed | F03.A0 | S — Synthetic modern coding of his documented failing memory; the cause is unknown, so the type is left unspecified. Stage and scores are synthetic. |
| Common cold, with two nights of increased confusion after an over-the-counter nighttime cold medicine containing diphenhydramine; resolved | resolved | confirmed | J00 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
| Progressive memory loss over about two years with decline in managing his work and affairs, under evaluation for dementia or mild cognitive impairment | resolved | confirmed | R41.3 | S — Synthetic presenting concern at the index visit, superseded by the dementia diagnosis at the four-week visit; the failing memory is documented (D). |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-05 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-05-05 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 2026-05-05 | Platelets [#/volume] in Blood by Automated count | 238 | 10*3/uL | 135-317 10*3/uL | Normal | S |
| 2026-05-05 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-05 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-05 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-05-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 76 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-05 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-05-05 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-05-05 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-05-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 2026-05-05 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 410 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-05-05 | Folate [Mass/volume] in Serum or Plasma | 12.4 | ng/mL | >=5.9 ng/mL | Normal | S |
| 2026-05-05 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-05-05 | Total score [MoCA] | 19 | {score} | S | ||
| 2026-05-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-09-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-09-15 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2026-09-15 | Cholesterol [Mass/volume] in Serum or Plasma | 196 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-09-15 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-09-15 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 118 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-09-15 | Triglyceride [Mass/volume] in Serum or Plasma | 120 | mg/dL | <=149 mg/dL | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-05 | Body height | 175 | cm | S |
| 2026-05-05 | Body weight | 72 | kg | S |
| 2026-05-05 | Body mass index (BMI) [Ratio] | 23.5 | kg/m2 | S |
| 2026-05-05 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-05-05 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-05-05 | Heart rate | 72 | /min | S |
| 2026-05-05 | Respiratory rate | 14 | /min | S |
| 2026-05-05 | Body temperature | 36.7 | Cel | S |
| 2026-05-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-06-02 | Body height | 175 | cm | S |
| 2026-06-02 | Body weight | 71.8 | kg | S |
| 2026-06-02 | Body mass index (BMI) [Ratio] | 23.4 | kg/m2 | S |
| 2026-06-02 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-06-02 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-02 | Heart rate | 70 | /min | S |
| 2026-06-02 | Respiratory rate | 14 | /min | S |
| 2026-06-02 | Body temperature | 36.6 | Cel | S |
| 2026-06-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-08-04 | Body height | 175 | cm | S |
| 2026-08-04 | Body weight | 71.2 | kg | S |
| 2026-08-04 | Body mass index (BMI) [Ratio] | 23.2 | kg/m2 | S |
| 2026-08-04 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-08-04 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-04 | Heart rate | 62 | /min | S |
| 2026-08-04 | Respiratory rate | 14 | /min | S |
| 2026-08-04 | Body temperature | 36.6 | Cel | S |
| 2026-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-10-27 | Body height | 175 | cm | S |
| 2026-10-27 | Body weight | 71 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 23.2 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 60 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-07-14 | Body height | 175 | cm | S |
| 2026-07-14 | Body weight | 71.4 | kg | S |
| 2026-07-14 | Body mass index (BMI) [Ratio] | 23.3 | kg/m2 | S |
| 2026-07-14 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-07-14 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-07-14 | Heart rate | 70 | /min | S |
| 2026-07-14 | Respiratory rate | 16 | /min | S |
| 2026-07-14 | Body temperature | 37.4 | Cel | S |
| 2026-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-15 | Body height | 175 | cm | S |
| 2026-09-15 | Body weight | 71 | kg | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 23.2 | kg/m2 | S |
| 2026-09-15 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-09-15 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-15 | Heart rate | 60 | /min | S |
| 2026-09-15 | Respiratory rate | 14 | /min | S |
| 2026-09-15 | Body temperature | 36.6 | Cel | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-05-05 | Cognitive evaluation for progressive memory loss: history from patient and caregiver, MoCA, function, mood, safety, and reversible-cause tests | finished | S |
| 2026-06-02 | Four-week follow-up: results and MRI review, diagnosis disclosure, and behavioral neurology consultation | finished | S |
| 2026-08-04 | Three-month dementia review: donepezil, safety plan, caregiver burden, and advance care planning | finished | S |
| 2026-10-27 | Six-month dementia review | finished | S |
| 2026-07-14 | Same-day sick visit for a head cold with night-time confusion | finished | S |
| 2026-09-15 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Reversible-cause tests (blood count, metabolic panel, vitamin B12, folate, TSH) and one non-contrast brain MRI; syphilis and HIV testing only with risk factors or atypical features | completed | GL-AAN-DEM-2001, GL-ALZ-PC-2025, GL-CMID-2026 | S |
| Behavioral neurology consultation to confirm the diagnosis, consider the type and biomarker testing, and advise on treatment and driving | completed | GL-ALZ-SC-2025, GL-AAN-DEM-2001, GL-AAN-DRIVE-2010 | S |
| Donepezil trial, 5 mg daily for four to eight weeks then 10 mg, with heart rate, fainting, gastrointestinal effects, weight, and sleep checked at each visit; avoid anticholinergic drugs, first-generation antihistamines, benzodiazepines, and sleeping pills (AGS Beers Criteria) | completed | GL-CMID-2026, GL-BEERS-2023 | S |
| Safety: stop driving at CDR 1, keep the home free of firearms, medical identification for wandering, supervised medicines and finances, and home safety | completed | GL-AAN-DRIVE-2010, GL-CMID-2026 | S |
| Caregiver support: Zarit Burden Interview at diagnosis and every six to twelve months, education, adult day program and respite, and Alzheimer's Association support services | completed | GL-CMID-2026, GL-ALZ-PC-2025 | S |
| Monitor on the CMID dementia schedule: medication review and neuropsychiatric screen at every visit; MoCA, ADL and IADL, CDR or FAST stage, depression screen, fall risk, driving, and advance care planning yearly; repeat tests or imaging only with a sudden change | completed | GL-CMID-2026 | S |
| Advance care planning while he can take part: name a health care agent and record his values and wishes | completed | GL-CMID-2026, GL-ALZ-PC-2025 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Complete the reversible-cause tests and brain MRI and discuss the diagnosis with him and his caregiver by the four-week visit | 2026-06-02 | completed | Tests and MRI showed no reversible cause; diagnosis of mild dementia of undetermined type discussed with both | S |
| A safety plan in place by the three-month review: no driving, medicines supervised, finances overseen, and medical identification worn | 2026-08-04 | completed | Stopped driving after the consultation; caregiver gives medicines from a weekly organizer and oversees bill paying with his agreement; medical identification bracelet worn | S |
| Donepezil at 10 mg daily without side effects and with resting heart rate 55 or above by the six-month review | 2026-10-27 | completed | On 10 mg for three months; heart rate 60; no nausea, diarrhea, weight loss, or vivid dreams | S |
| Caregiver burden assessed and support in place by the six-month review | 2026-10-27 | completed | Zarit Burden Interview 24 at three months; caregiver education program completed and two days a week of adult day program begun | S |
| Name a health care agent and record his values and wishes while he can take full part, by the three-month review | 2026-08-04 | completed | Health care agent named and his wishes recorded at the three-month review | S |